NEW YORK (GenomeWeb News) – Abbott reported this morning that its first-quarter molecular diagnostics sales increased around 1 percent year over year, while its overall diagnostics revenues climbed a little more than 4 percent.

The pharmaceuticals, diagnostics, and medical devices firm had total revenues of $5.38 billion, up 2 percent from $5.28 billion for the first quarter of 2012. Sales for its diagnostics business, overall, were $1.09 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.